Synairgen plc Director/PDMR Shareholding (9105Z)
28 Enero 2022 - 1:00AM
UK Regulatory
TIDMSNG
RNS Number : 9105Z
Synairgen plc
28 January 2022
28 January 2022
Synairgen plc
("Synairgen" or the "Company")
Director/PDMR Dealing
Southampton, UK - 28 January 2022: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001 (inhaled interferon-beta or
IFN-beta) for the treatment of COVID-19 as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered
directly into the lungs, announces that it was notified on 27
January 2022 that the spouse of Brooke Clarke, Senior Vice
President, Head of Communications and PDMR, had purchased 8,520
ordinary shares of 1 pence each in the Company ("Ordinary Shares")
at an average price of 189.717p.
Following the purchase, the spouse of Brooke Clarke has a total
interest over 8,520 Ordinary Shares, representing 0.004 per cent.
of the Company's issued share capital.
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Tel: +44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: +44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516 606 6545
The notification set out below is provided in accordance with
the requirements of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Thomas Clarke
------------------------------------------- -----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------
a) Position/status Person closely associated with Brooke
Clarke, a PDMR
------------------------------------------- -----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------- -----------------------------------------
3 Details of issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Synairgen plc
------------------------------------------- -----------------------------------------
b) LEI 213800IMMTOPPDF8HD24
------------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted.
--------------------------------------------------------------------------------------
a) Description of Ordinary shares of 1p
the financial
instrument, type
of instrument
Identification ISIN: GB00B0381Z20
code
------------------------------------------- -----------------------------------------
b) Nature of the Purchase of shares by spouse
transaction
------------------------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------- --------------------- ------------------
GBP1.8974 7,899
GBP1.8942 621
-------------------------------------------------------------------------- ------------------
d) Aggregated information
* Aggregated volume 8,520 Ordinary Shares
GBP16,163.86p
* Price
------------------------------------------- -----------------------------------------
e) Date of the transaction 27 January 2022
------------------------------------------- -----------------------------------------
f) Place of the transaction XLON
------------------------------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAPFXADLAEFA
(END) Dow Jones Newswires
January 28, 2022 02:00 ET (07:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
